Intermittent Fasting and APOE4: What the Evidence Supports

Patient Guide · Nutrition · Evidence Review

Intermittent Fasting and APOE4: What the Evidence Supports

By Brian Paquette, DO, MPH

Intermittent fasting is one of the most common strategies APOE ε4 carriers ask about. The idea is appealing: fasting raises ketones, ketones can fuel the brain, and the ε4 brain is thought to handle glucose less efficiently. This guide separates what has been shown in human trials from what remains a hypothesis, and explains where fasting reasonably fits in a brain-health plan.

Key points

1. No randomized trial has shown that intermittent fasting prevents or delays Alzheimer’s disease in APOE ε4 carriers.

2. Fasting produces modest weight loss. In pooled trials it has not clearly outperformed ordinary calorie reduction for weight or blood glucose.

3. When ketone-raising treatments were tested in people with Alzheimer’s disease, early signals of benefit appeared in ε4 non-carriers, not carriers, and the confirmatory trial was negative.

4. The best-supported approach for ε4 carriers remains a multidomain program: dietary pattern, exercise, cognitive activity, and vascular risk management.

5. Fasting is a reasonable optional tool for metabolic goals in suitable adults. It is not a first step, and it is not appropriate for everyone.

What intermittent fasting means

Intermittent fasting describes eating schedules rather than specific foods. The three patterns studied most often are:

  • Time-restricted eating: all food is eaten within a set daily window, with an overnight fast making up the remainder.
  • 5:2 fasting: usual intake on five days of the week and marked calorie restriction on two non-consecutive days.
  • Alternate-day fasting: fasting or very-low-calorie days alternate with usual eating days.

The proposed mechanism is “metabolic switching”: after a sufficiently long fast, the body shifts from relying mainly on glucose toward fatty acids and ketone bodies. This concept is described in detail in a widely cited review.[1] Much of the supporting evidence in that literature comes from animal studies and short-term human studies of metabolic markers, not from trials with dementia outcomes.

What fasting reliably does: weight and metabolic markers

A Cochrane systematic review pooled 18 randomized trials with 1,125 participants, with follow-up of four weeks to six months.[2] Its conclusions were measured:

  • Compared with unrestricted eating, fasting reduced body weight by about 2.9 kg in the short term (low-certainty evidence).
  • Compared with ordinary continuous calorie restriction, there was no clinically significant difference in weight or glucose.
  • None of the trials reported heart attack, stroke, heart failure, or death as outcomes.

In practical terms, fasting is one workable way to reduce calorie intake. For some people a defined eating window is easier to sustain than counting calories, and that is a legitimate reason to choose it. It should not be presented as having proven cardiovascular or cognitive advantages over other methods of achieving the same weight and metabolic targets.

The ketone hypothesis and APOE ε4

Reduced brain glucose metabolism is a recognized early feature of Alzheimer’s disease. The hypothesis follows naturally: if glucose use is impaired, supplying ketones might compensate. Fasting is one way to raise ketones; medium-chain triglycerides (MCT) are another. The ketone approach has been tested directly in randomized trials, and the results by APOE genotype are the opposite of what many carriers have been told.

  • Reger et al., 2004. In 20 adults with Alzheimer’s disease or mild cognitive impairment, a single MCT drink improved ADAS-Cog performance in ε4 non-carriers but not in ε4 carriers (P = 0.04).[3]
  • Henderson et al., 2009. In 152 participants with mild to moderate Alzheimer’s disease, the ketogenic compound AC-1202 produced a 3.36-point ADAS-Cog advantage at day 90 among ε4 non-carriers in the intention-to-treat analysis. The benefit was concentrated in non-carriers.[4]
  • NOURISH AD, 2020. The confirmatory trial enrolled 413 participants and set its primary endpoint in ε4 non-carriers, the group that had appeared to respond. It was negative (difference −0.761 points, P = 0.2458).[5]

These were trials of ketone-raising supplements in people who already had Alzheimer’s disease, not trials of fasting in healthy carriers. They do not prove that fasting is ineffective. They do show that the central rationale offered to ε4 carriers, that ketones will rescue cognition in the ε4 brain, has not held up when tested in people.

Direct trials of fasting and cognition

Human trials that measure cognition are few and small.

  • Time-restricted eating in mild cognitive impairment. A pilot randomized trial assigned 46 older adults with mild cognitive impairment to a 15-hour daily fast or usual eating for 12 weeks.[6] The fasting group improved by 1.70 points on the Montreal Cognitive Assessment relative to controls. The authors themselves advise caution because of the small sample. Participants knew their assignment, the control group received no intervention, and the published summary reports no analysis by APOE genotype.
  • Fasting combined with a ketogenic diet in Alzheimer’s disease. A 60-patient randomized trial combined a plant-rich ketogenic diet with intermittent fasting for six months and reported a between-group difference on the Mini-Mental State Examination.[7] Because the two interventions were delivered together, the trial cannot show what fasting contributed.

These are hypothesis-generating results. They justify larger trials. They do not justify a recommendation.

What has stronger evidence for APOE ε4 carriers

The FINGER trial randomized 1,260 at-risk adults aged 60 to 77 to a two-year program of dietary counseling, exercise, cognitive training, and vascular risk monitoring, or to general health advice.[8] The intervention group showed a small but statistically significant cognitive advantage. FINGER did not include fasting.

In the prespecified APOE analysis, the benefit was evident among the 362 ε4 carriers, and the effect did not differ significantly between carriers and non-carriers.[9] The appropriate conclusion is that carriers benefit from lifestyle intervention despite their genetic risk, not that they are proven to benefit more.

On diet specifically, an umbrella review of systematic reviews found that, with the exception of the Mediterranean diet, dietary interventions including ketogenic diets and supplements were generally not effective in older ε4 carriers.[10] The authors also identified a shortage of studies in middle-aged, cognitively healthy carriers, so the question remains open for that group.

Related reading: The APOE4 Carrier and the Nutrition Dilemma, heart health and the brain by genotype, and Exercise and Your Brain.

Where fasting fits in practice

A sensible order of priorities for an ε4 carrier, to review with a physician:

1. Vascular and metabolic risk. Blood pressure, LDL cholesterol or ApoB, blood glucose, and body weight.

2. Dietary pattern. A Mediterranean-style pattern has the most consistent support.

3. Exercise. Both aerobic and resistance training, as in FINGER.

4. Cognitive and social engagement, and sleep.

5. Optional: an eating schedule. If weight or glucose control is a goal and a defined eating window suits you, time-restricted eating is a reasonable method. Choose it for metabolic reasons and for sustainability, not on the expectation of a proven cognitive benefit.

If you do try it, a moderate overnight fast is the most conservative starting point. Maintain adequate protein intake and resistance exercise, because unintended loss of muscle is a particular concern in older adults. No specific fasting duration has been validated for ε4 carriers.

Who should not fast without medical supervision

  • People taking insulin or other glucose-lowering medications that can cause hypoglycemia
  • People with type 1 diabetes
  • Anyone with a current or past eating disorder
  • Those who are pregnant or breastfeeding
  • People who are underweight, frail, or losing weight unintentionally
  • People with dementia whose food intake is already reduced

The Cochrane authors specifically called for more research on the safety of fasting in groups such as people with diabetes or eating disorders.[2]

Bottom line: Intermittent fasting is a legitimate option for weight and metabolic management, with effects similar to other forms of calorie reduction. For APOE ε4 carriers, its promise for brain protection rests on mechanism and small early trials, and the related ketone trials did not favor carriers. Build the plan on vascular risk control, a Mediterranean-style diet, and exercise. Treat fasting as an optional addition to that foundation.

This article is for education and is not a substitute for individual medical advice. Discuss any change in diet or eating schedule with your physician, particularly if you take medication for diabetes. Last reviewed November 2026.

References

1. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019;381(26):2541–2551. doi:10.1056/NEJMra1905136

2. Allaf M, Elghazaly H, Mohamed OG, et al. Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2021;1(1):CD013496. doi:10.1002/14651858.CD013496.pub2

3. Reger MA, Henderson ST, Hale C, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004;25(3):311–314. doi:10.1016/S0197-4580(03)00087-3

4. Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009;6:31. doi:10.1186/1743-7075-6-31

5. Henderson ST, Morimoto BH, Cummings JL, Farlow MR, Walker J. A placebo-controlled, parallel-group, randomized clinical trial of AC-1204 in mild-to-moderate Alzheimer’s disease. J Alzheimers Dis. 2020;75(2):547–557. doi:10.3233/JAD-191302

6. Wang J, Wang F, Shi M, et al. Effects of 15:9 time-restricted eating on cognitive function and anthropometric parameters among the elderly with mild cognitive impairment: an assessor-blinded, pilot randomized controlled trial. BMC Geriatr. 2025;25(1):1063. doi:10.1186/s12877-025-06788-7

7. Tağraf B, Kaygusuz D, Yerlikaya D, Oğul ÖE, Hanoğlu L. The effect of simultaneous application of plant-rich ketogenic diet and intermittent fasting on early-to-mid-stage Alzheimer’s disease: a randomised controlled trial. J Nutr Health Aging. 2026;30(9):100930. doi:10.1016/j.jnha.2026.100930

8. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–2263. doi:10.1016/S0140-6736(15)60461-5

9. Solomon A, Turunen H, Ngandu T, et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 2018;75(4):462–470. doi:10.1001/jamaneurol.2017.4365

10. Urich TJ, Tsiknia AA, Ali N, et al. APOE ε4 and dietary patterns in relation to cognitive function: an umbrella review of systematic reviews. Nutr Rev. 2025;83(7):e2113–e2126. doi:10.1093/nutrit/nuae156

Just learned you carry APOE4?

Get the free physician’s guide Your First 30 Days After an APOE4 Result, plus one evidence update a month.

No spam. Unsubscribe anytime.

Just learned you carry APOE4?

Get the free physician’s guide Your First 30 Days After an APOE4 Result, plus one evidence update a month.

No spam. Unsubscribe anytime.

Similar Posts